Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: A cross-sectional study

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Yu, Shu yang ^a   Zuo, Li jun ^a   Wang, Fang ^a   Chen, Ze jie ^a   Hu, Yang ^a   Wang, Ya jie ^a   Wang, Xiao min ^a,b,d   Zhang, Wei ^a,b,c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^c Beijing Key Laboratory for Parkinson's Disease   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cerebrospinal fluid; Cognitive impairment; Free radicals; Neuroinflammatory factors; Parkinson's disease; Pathological proteins

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; FREE RADICAL; GAMMA INTERFERON; HYDROGEN PEROXIDE; HYDROXYL RADICAL; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEUROINFLAMMATORY FACTOR; NITRIC OXIDE; PATHOLOGICAL PROTEIN; PROSTAGLANDIN E2; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; NERVE PROTEIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MONTREAL COGNITIVE ASSESSMENT; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; AGED; COGNITION DISORDERS; COMPLICATION; MIDDLE AGED;

AGED; BIOLOGICAL MARKERS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; FREE RADICALS; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; PARKINSON DISEASE;

EID: 84901586086     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-113     Document Type: Article

References (34)

1. Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010, 75:1062-1069. 10.1212/WNL.0b013e3181f39d0e, 2942065, 20855849.
2. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005, 62:1160-1163. discussion 1167, 10.1001/archneur.62.7.1160, 16009779.
3. Halliday GM, McCann H. The progression of pathology in Parkinson's disease. Ann N Y Acad Sci 2010, 1184:188-195. 10.1111/j.1749-6632.2009.05118.x, 20146698.
4. Block ML, Hong JS. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol 2005, 76:77-98. 10.1016/j.pneurobio.2005.06.004, 16081203.
5. Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Neurotox Res 2011, 19:63-72. 10.1007/s12640-009-9140-z, 3603276, 19957214.
6. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O. Cerebrospinal fluid inflammatory markers in Parkinson's disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013, 33:183-189.
7. Hritcu L, Ciobica A, Stefan M, Mihasan M, Palamiuc L, Nabeshima T. Spatial memory deficits and oxidative stress damage following exposure to lipopolysaccharide in a rodent model of Parkinson's disease. Neurosci Res 2011, 71:35-43. 10.1016/j.neures.2011.05.016, 21663772.
8. Kaur H, Chauhan S, Sandhir R. Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson's disease. Neurochem Res 2011, 36:1435-1443. 10.1007/s11064-011-0469-3, 21484267.
9. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55:181-184. 10.1136/jnnp.55.3.181, 1014720, 1564476.
10. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012, 27:349-356. 10.1002/mds.24893, 3641655, 22275317.
11. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees A, Levy R, Litvan I, Mizuno Y, McKeith IG, Olanow CW, Poewe W, Sampaio C, Tolosa E, Emre M. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007, 22:2314-2324. 10.1002/mds.21844, 18098298.
12. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007, 130:1787-1798. 10.1093/brain/awm111, 17535834.
13. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, Marti MJ, Valldeoriola F, Bargallo N, Junque C. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol 2008, 255:1324-1331. 10.1007/s00415-008-0885-8, 18821043.
14. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010, 9:1200-1213. 10.1016/S1474-4422(10)70212-X, 20880750.
15. Bondi MW, Kaszniak A, Bayles KA, Vance KT. Contributions of frontal system dysfunction to memory and perceptual abilities in parkinson's disease. Neuropsychology 1993, 7:14.
16. Cronin-Golomb A, Braun AE. Visuospatial dysfunction and problem solving in Parkinson's disease. Neuropsychology 1997, 11:44-52.
17. Crucian GP, Okun MS. Visual-spatial ability in Parkinson's disease. Front Biosci 2003, 8:s992-s997. 10.2741/1171, 12957858.
18. Evans JR, Mason SL, Williams-Gray CH, Foltynie T, Brayne C, Robbins TW, Barker RA. The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 2011, 82:1112-1118. 10.1136/jnnp.2011.240366, 21593513.
19. Armstrong MJ, Naglie G, Duff-Canning S, Meaney C, Gill D, Eslinger PJ, Zadikoff C, Mapstone M, Chou KL, Persad C, Litvan I, Mast BT, Fox S, Tang-Wai DF, Marras C. Roles of education and IQ in cognitive reserve in Parkinson's disease-mild cognitive impairment. Dement Geriatr Cogn Disord Extra 2012, 2:343-352.
20. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C. CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75:1055-1061. 10.1212/WNL.0b013e3181f39a78, 2942062, 20720189.
21. Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010, 25:2682-2685. 10.1002/mds.23287, 2978754, 20818673.
22. Jellinger K. Heterogenous mechanisms of mild cognitive impairment in Parkinson's disease. J Neural Transm 2012, 119:2.
23. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397. 10.1016/S1474-4422(09)70062-6, 19296921.
24. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994, 165:208-210. 10.1016/0304-3940(94)90746-3, 8015728.
25. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995, 202:17-20. 10.1016/0304-3940(95)12192-7, 8787820.
26. Muller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998, 98:142-144.
27. Barnum CJ, Tansey MG. Modeling neuroinflammatory pathogenesis of Parkinson's disease. Prog Brain Res 2010, 184:113-132.
28. Jefferson AL, Massaro JM, Beiser AS, Seshadri S, Larson MG, Wolf PA, Au R, Benjamin EJ. Inflammatory markers and neuropsychological functioning: the Framingham Heart Study. Neuroepidemiology 2011, 37:21-30. 10.1159/000328864, 3142099, 21757961.
29. Kamer AR, Morse DE, Holm-Pedersen P, Mortensen EL, Avlund K. Periodontal inflammation in relation to cognitive function in an older adult Danish population. J Alzheimers Dis 2012, 28:613-624.
30. Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP. Sleep disturbances and interleukin 6 receptor inhibition in rheumatoid arthritis. J Rheumatol 2012, 39:60-62. 10.3899/jrheum.110617, 22133618.
31. Cibelli M, Fidalgo AR, Terrando N, Ma D, Monaco C, Feldmann M, Takata M, Lever IJ, Nanchahal J, Fanselow MS, Maze M. Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol 2010, 68:360-368. 10.1002/ana.22082, 20818791.
32. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006, 21:404-412. 10.1016/j.nbd.2005.08.002, 16182554.
33. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O. Cerebrospinal fluid inflammatory markers in Parkinson's disease - Associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 2013, 13:7.
34. Gironi M, Bianchi A, Russo A, Alberoni M, Ceresa L, Angelini A, Cursano C, Mariani E, Nemni R, Kullmann C, Farina E, Martinelli Boneschi F. Oxidative imbalance in different neurodegenerative diseases with memory impairment. Neurodegener Dis 2011, 8:129-137. 10.1159/000319452, 20838029.